EA030613B1 - Новый способ получения соединений для применения при лечении рака - Google Patents
Новый способ получения соединений для применения при лечении рака Download PDFInfo
- Publication number
- EA030613B1 EA030613B1 EA201590700A EA201590700A EA030613B1 EA 030613 B1 EA030613 B1 EA 030613B1 EA 201590700 A EA201590700 A EA 201590700A EA 201590700 A EA201590700 A EA 201590700A EA 030613 B1 EA030613 B1 EA 030613B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- formula
- compound
- compounds
- group
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713104P | 2012-10-12 | 2012-10-12 | |
| PCT/US2013/064866 WO2014059422A1 (en) | 2012-10-12 | 2013-10-14 | Novel process for making compounds for use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201590700A1 EA201590700A1 (ru) | 2015-09-30 |
| EA030613B1 true EA030613B1 (ru) | 2018-08-31 |
Family
ID=49474740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590700A EA030613B1 (ru) | 2012-10-12 | 2013-10-14 | Новый способ получения соединений для применения при лечении рака |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9771347B2 (enExample) |
| EP (1) | EP2909188B1 (enExample) |
| JP (2) | JP6300042B2 (enExample) |
| KR (1) | KR102204520B1 (enExample) |
| CN (2) | CN108948043B (enExample) |
| AU (1) | AU2013328929B2 (enExample) |
| BR (1) | BR112015008113B1 (enExample) |
| CA (1) | CA2889466C (enExample) |
| CL (1) | CL2015000926A1 (enExample) |
| CR (2) | CR20200237A (enExample) |
| EA (1) | EA030613B1 (enExample) |
| ES (1) | ES2671502T3 (enExample) |
| GE (1) | GEP201706690B (enExample) |
| HK (1) | HK1213567A1 (enExample) |
| HR (1) | HRP20180670T1 (enExample) |
| IL (1) | IL238116B (enExample) |
| IN (1) | IN2015DN03928A (enExample) |
| MA (1) | MA38085B1 (enExample) |
| MX (2) | MX372708B (enExample) |
| MY (1) | MY186549A (enExample) |
| NZ (1) | NZ706723A (enExample) |
| PE (3) | PE20151494A1 (enExample) |
| PH (1) | PH12015500785A1 (enExample) |
| PL (1) | PL2909188T3 (enExample) |
| SA (1) | SA515360271B1 (enExample) |
| SG (1) | SG11201502795VA (enExample) |
| SI (1) | SI2909188T1 (enExample) |
| TR (1) | TR201807861T4 (enExample) |
| UA (1) | UA115455C2 (enExample) |
| WO (1) | WO2014059422A1 (enExample) |
| ZA (1) | ZA201502349B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20180670T1 (hr) | 2012-10-12 | 2018-07-13 | Exelixis Inc. | Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| IL256299B2 (en) | 2015-06-30 | 2023-11-01 | Genentech Inc | Immediate-release tablets containing a drug and processes for creating the tablets |
| CN105330643B (zh) * | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
| CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
| CN109689102A (zh) | 2016-08-12 | 2019-04-26 | 基因泰克公司 | Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法 |
| WO2018064299A1 (en) | 2016-09-29 | 2018-04-05 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
| EP4304592A1 (en) | 2021-03-09 | 2024-01-17 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
| US20240366609A1 (en) | 2021-04-06 | 2024-11-07 | Genentech, Inc. | Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044515A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1563587A (en) * | 1924-09-20 | 1925-12-01 | Raney Murray | Method of preparing catalytic material |
| US1628190A (en) * | 1926-05-14 | 1927-05-10 | Raney Murray | Method of producing finely-divided nickel |
| US1915473A (en) * | 1930-12-31 | 1933-06-27 | Raney Murray | Method of preparing catalytic material |
| US4510139A (en) | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| CN1094487C (zh) | 1994-04-01 | 2002-11-20 | 盐野义制药株式会社 | 肟衍生物和含有其作为活性成分的杀菌剂 |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| WO1998037881A1 (en) | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| AU757046B2 (en) | 1997-07-01 | 2003-01-30 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| JP2002509536A (ja) | 1997-07-01 | 2002-03-26 | ワーナー−ランバート・カンパニー | ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用 |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US6974878B2 (en) | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
| TR200101704T2 (tr) | 1998-12-15 | 2001-11-21 | Warner-Lambert Company | Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı |
| IL143236A0 (en) | 1998-12-16 | 2002-04-21 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
| HRP20010473A2 (en) | 1998-12-22 | 2002-08-31 | Warner Lambert Co | Combination chemotherapy |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| DE69924641D1 (de) | 1999-01-07 | 2005-05-12 | Warner Lambert Company Llc Mor | Behandlung von asthma anhand von mek-inhibitoren |
| AU2203800A (en) | 1999-01-07 | 2000-07-24 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| IL144214A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| AU2201500A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| GEP20032999B (en) | 1999-01-13 | 2003-06-25 | Warner Lambert Co | 1-Heterocycle Substituted Diarylamines |
| CA2349180A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | Anthranilic acid derivatives |
| EP1202732A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
| AU6068600A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| DK1202724T3 (da) | 1999-07-16 | 2004-01-26 | Warner Lambert Co | Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer |
| KR20020012315A (ko) | 1999-07-16 | 2002-02-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 |
| DE60040676D1 (de) | 1999-09-17 | 2008-12-11 | Millennium Pharm Inc | BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa |
| AU2001247372A1 (en) | 2000-03-15 | 2001-09-24 | Warner Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| WO2002006213A2 (en) | 2000-07-19 | 2002-01-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| KR20030059115A (ko) * | 2000-08-25 | 2003-07-07 | 워너-램버트 캄파니 엘엘씨 | Ｎ-아릴-안트라닐산 및 그의 유도체의 제조 방법 |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
| DE10141266A1 (de) | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
| US7085492B2 (en) | 2001-08-27 | 2006-08-01 | Ibsen Photonics A/S | Wavelength division multiplexed device |
| PL370549A1 (en) | 2001-10-31 | 2005-05-30 | Pfizer Products Inc. | Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome |
| BR0307060A (pt) | 2002-01-23 | 2004-10-26 | Warner Lambert Co | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico |
| DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| TWI343377B (en) | 2002-03-13 | 2011-06-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| AU2003238915B2 (en) | 2002-06-11 | 2008-02-21 | Merck & Co., Inc. | (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| US20060094674A1 (en) | 2002-07-05 | 2006-05-04 | Neel Benjamin G | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| MXPA05009459A (es) | 2003-03-03 | 2006-05-17 | Array Biopharma Inc | Inhibidores de p38 y sus metodos de uso. |
| JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| EP1641804A1 (en) | 2003-06-20 | 2006-04-05 | Celltech R & D Limited | Thienopyridone derivatives as kinase inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| BRPI0412851A (pt) | 2003-07-24 | 2006-10-03 | Warner Lambert Co | benzamidazóis de n-metila-substituìdos |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| WO2005028426A1 (ja) | 2003-09-19 | 2005-03-31 | Chugai Seiyaku Kabushiki Kaisha | 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| NZ547481A (en) | 2003-11-19 | 2009-12-24 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN100509808C (zh) | 2003-12-08 | 2009-07-08 | 霍夫曼-拉罗奇有限公司 | 新型噻唑衍生物 |
| TWI361066B (en) | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| AR051248A1 (es) * | 2004-10-20 | 2007-01-03 | Applied Research Systems | Derivados de 3-arilamino piridina |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| HRP20180670T1 (hr) | 2012-10-12 | 2018-07-13 | Exelixis Inc. | Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka |
| KR102264639B1 (ko) | 2014-02-07 | 2021-06-11 | 스미또모 가가꾸 가부시끼가이샤 | (r)-1,1,3-트리메틸-4-아미노인단의 제조 방법 |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2013
- 2013-10-14 HR HRP20180670TT patent/HRP20180670T1/hr unknown
- 2013-10-14 IN IN3928DEN2015 patent/IN2015DN03928A/en unknown
- 2013-10-14 MA MA38085A patent/MA38085B1/fr unknown
- 2013-10-14 EA EA201590700A patent/EA030613B1/ru not_active IP Right Cessation
- 2013-10-14 EP EP13780303.7A patent/EP2909188B1/en active Active
- 2013-10-14 CN CN201810758236.XA patent/CN108948043B/zh active Active
- 2013-10-14 KR KR1020157012066A patent/KR102204520B1/ko active Active
- 2013-10-14 MX MX2015004660A patent/MX372708B/es active IP Right Grant
- 2013-10-14 TR TR2018/07861T patent/TR201807861T4/tr unknown
- 2013-10-14 NZ NZ706723A patent/NZ706723A/en unknown
- 2013-10-14 MY MYPI2015000897A patent/MY186549A/en unknown
- 2013-10-14 CN CN201380064338.7A patent/CN104837826B/zh active Active
- 2013-10-14 HK HK16101572.6A patent/HK1213567A1/zh unknown
- 2013-10-14 JP JP2015536988A patent/JP6300042B2/ja active Active
- 2013-10-14 CR CR20200237A patent/CR20200237A/es unknown
- 2013-10-14 CA CA2889466A patent/CA2889466C/en active Active
- 2013-10-14 PE PE2015000485A patent/PE20151494A1/es active IP Right Grant
- 2013-10-14 AU AU2013328929A patent/AU2013328929B2/en active Active
- 2013-10-14 PL PL13780303T patent/PL2909188T3/pl unknown
- 2013-10-14 GE GEAP201313824A patent/GEP201706690B/en unknown
- 2013-10-14 ES ES13780303.7T patent/ES2671502T3/es active Active
- 2013-10-14 SI SI201331045T patent/SI2909188T1/en unknown
- 2013-10-14 SG SG11201502795VA patent/SG11201502795VA/en unknown
- 2013-10-14 BR BR112015008113-4A patent/BR112015008113B1/pt active IP Right Grant
- 2013-10-14 UA UAA201504532A patent/UA115455C2/uk unknown
- 2013-10-14 PE PE2019002024A patent/PE20191818A1/es unknown
- 2013-10-14 WO PCT/US2013/064866 patent/WO2014059422A1/en not_active Ceased
-
2015
- 2015-04-02 IL IL238116A patent/IL238116B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/02349A patent/ZA201502349B/en unknown
- 2015-04-08 PH PH12015500785A patent/PH12015500785A1/en unknown
- 2015-04-10 MX MX2020005533A patent/MX2020005533A/es unknown
- 2015-04-12 SA SA515360271A patent/SA515360271B1/ar unknown
- 2015-04-13 CL CL2015000926A patent/CL2015000926A1/es unknown
- 2015-04-13 US US14/684,826 patent/US9771347B2/en active Active
- 2015-05-11 CR CR20150245A patent/CR20150245A/es unknown
-
2017
- 2017-08-25 US US15/686,333 patent/US10239858B2/en active Active
- 2017-12-06 JP JP2017234208A patent/JP2018052973A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,215 patent/US10793541B2/en active Active
- 2019-08-08 PE PE2019001563A patent/PE20200387A1/es unknown
-
2020
- 2020-08-26 US US17/003,570 patent/US11414396B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044515A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11414396B2 (en) | Process for making compounds for use in the treatment of cancer | |
| EP3567030B1 (en) | Quinazoline compound for egfr inhibition | |
| JP6761448B2 (ja) | アザインドールを作製するための方法および中間体 | |
| CN115448923B (zh) | 嘧啶并环化合物及其制备方法和应用 | |
| AU2014327235B2 (en) | New 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors | |
| CN121843945A (zh) | 具有抗kras突变肿瘤活性的化合物 | |
| JP2021513555A5 (ja) | ピリミジン縮合環式化合物及びその製造方法、並びに使用 | |
| CA3217417A1 (en) | Compounds for targeting degradation of bruton's tyrosine kinase | |
| JP2016537369A (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 | |
| EP3115362B1 (en) | Piperidine derivatives as orexin receptor antagonist | |
| EP3463341A1 (en) | Aminoacylindazole immunomodulators for treatment of autoimmune diseases | |
| CN104557871B (zh) | 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途 | |
| EP4209485A1 (en) | Compound having antitumor activity and use thereof | |
| HK1213878B (en) | Novel process for making compounds for use in the treatment of cancer | |
| EP3653626B1 (en) | Novel 1h-pyrazolopyridine derivative and pharmaceutical composition containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG TJ TM |